Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 13/20 | 0.52 |
| ▸ | CALCR | P30988 | 13/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | GNRHR | P30968 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381927 | 0.94 | RAMP3 (0.54) | RENRAMP3CALCRCTSDGNRHR | |
| SCHEMBL13811921 | 0.90 | CXCR4 (0.57) | RAMP3CALCRCXCR4 | |
| SCHEMBL15381913 | 0.88 | RAMP3 (0.46) | RENRAMP3CALCRCTSDGNRHR | |
| SCHEMBL29362916 | 0.81 | NPY2R (0.61) | RAMP3CALCRCXCR4 | |
| SCHEMBL22300350 | 0.77 | DPP4 (0.56) | RENCTSDPLK1 | |
| SCHEMBL30446656 | 0.76 | OPRM1 (0.48) | RAMP3CALCR | |
| SCHEMBL17931727 | 0.76 | CXCR4 (0.54) | RAMP3CALCRCXCR4 | |
| SCHEMBL16350002 | 0.76 | OPRD1 (0.46) | CXCR4 | |
| SCHEMBL31031589 | 0.75 | F2 (0.61) | RAMP3CALCRCXCR4 | |
| SCHEMBL7849192 | 0.75 | REN (0.65) | RENCTSDPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266557-A1 | NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE | NORTHWESTERN UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266557-A1 | NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE | NORTHWESTERN UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266557-A1 | NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE | BMP1, ACVRL1, BMP2 | REN 4259/4885RAMP3 1689/4885CALCR 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.